The Johns Hopkins-led and NIH funded OUtMATCH study led to the development of Xolair, a groundbreaking drug that reduces the ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.